GLPwatch

Protection of exenatide for retinal ganglion cells with different glucose concentrations.

Peptides · 2012

Last updated 2026-05-28

A lab study found that exenatide, a GLP-1 drug, protected retinal ganglion cells from damage caused by high or low glucose levels. The best protective dose was 0.5 micrograms per milliliter, and the drug helped prevent cell death and changes in mitochondria. However, a blocking agent called Exendin (9-39) reduced these protective effects.

AI summary of the abstract below.

JournalPeptides, 2012
Citations28
Relative citation ratio1.05
NIH percentile52
Molecules exenatide
Conditions studied Type 2 Diabetes

Abstract

Exendin-4 is a peptide resembling glucagon-like peptide-1 (GLP-1), which has protective effects on nerve cells. However, the effects of Exendin-4 on retinal ganglion cells (RGC) are still under clear. The purpose of the present study is to demonstrate that exenatide prevents high- or low-glucose-induced retinal ganglion cell impairment. We observed the expression of GLP-1R in RGC-5 cells by immunofluorescence and Western blot. To investigate the effect of exenatide on RGC-5 cells incubated different glucose concentrations, CCK-8 measured the survival rates and electron microscopy detected cellular injury. The expression levels of Bcl-2 and Bax were analyzed by immunocytochemistry and Western blot. Exenatide protects RGC-5 from high- or low-glucose-induced cellular injury and the optimum concentration was 0.5μg/ml. Exenatide can inhibit high- or low-glucose-induced mitochondrial changes. Exenatide protects RGC-5 from high- or low-glucose-induced Bax increased and Bcl-2 decreased. Furthermore, the protective effect of exenatide could be inhibited by Exendin (9-39). These findings indicate that exenatide shows a neuroprotective effect for different glucose concentrations-induced RGC-5 cells injury. Exenatide could protect RGC-5 cells from degeneration or death, which may protect retinal function and have a potential value for patients with diabetic retinopathy.

Verbatim abstract via PubMed 22727809 ↗

Related research